SEARCH

SEARCH BY CITATION

References

  • 1
    Deuschl G, Krack P. Morbus Parkinson. In: Hopf HC et al., eds. Neurologie in Praxis und Klinik, Vol. 2. Stuttgart, New York: Georg Thieme Company, 1999:4969.
  • 2
    Braak H, Ghebremedhin E, Rüb U, Bratzke HJ, del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:12134.
  • 3
    Borghammer P. Perfusion and metabolism imaging studies in Parkinson's disease. Dan Med J 2012;59:B4466.
  • 4
    Fujita M, Ichise M, van Dyck CH et al. Quantification of nicotinergic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 2003;30:16209.
  • 5
    Mamede M, Ishizu K, Ueda M et al. Quantification of human nicotinic acetylcholine receptors with 123I-5IA-SPECT. J Nucl Med 2004;45:145870.
  • 6
    Staley JK, van Dyck CH, Weinzimmer D et al. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med 2005;46:146672.
  • 7
    Fujita M, Ichise M, Zoghbi SS et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 2006;59:1747.
  • 8
    Kas A, Bottlaender M, Gallezot JD et al. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab 2009;29:16018.
  • 9
    Oishi N, Hashikawa K, Yoshida H et al. Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT. J Neurol Sci 2007;256:5260.
  • 10
    Mukhin AG, Gündisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS. 5-iodo-A-85380, an α4β2 subtype-ligand for nicotinic acetylcholine receptors. Mol Pharmacol 2000;57:6429.
  • 11
    Pimlott SL, Piggott M, Owens J et al. Nicotinic acetylcholine receptor distribution in Alzheimer′s disease, dementia with Lewy bodies, Parkinson's disease and vascular dementia: In vitro binding study using 5-[125I]-A-85380. Neuropsychopharmacology 2004;29:10816.
  • 12
    Schmaljohann J, Gündisch D, Minnerop M et al. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Nucl Med Biol 2006;33:3059.
  • 13
    Meyer PM, Strecker K, Kendziorra K et al. Reduced alpha4beta2-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009;66:86677.
  • 14
    Morris JC, Heyman A, Mohs RC et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:115965.
  • 15
    Hughes A, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:1814.
  • 16
    Miah IP, Olde DK, Stoffers D, Deijen JB, Berendse HW. Early-stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy. Eur J Neurol 2012;19:5106.
  • 17
    Molloy SA, Rowan EN, O'brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:13238.
  • 18
    Morrison CE, Borod JC, Brin MF, Hälbig TD, Olanow CW. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD). J Neural Transm 2004;111:133341.
  • 19
    Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;25:63843.
  • 20
    Berres M, Monsch AU, Bernasconi F, Thalmann B, Stähelin HB. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. Stud Health Technol Inform 2000;77:1959.
  • 21
    Bohnen NI, Albin RL. The cholinergic system and Parkinson's disease. Behav Brain Res 2011;221:56473.
  • 22
    Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986;47:26377.
  • 23
    Bohnen NI, Müller ML, Kotagal V et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012;32:160917.
  • 24
    Kotagal V, Müller ML, Kaufer DI, Koeppe RA, Bohnen NI. Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders. Neurosci Lett 2012;514:16972.
  • 25
    Müller MLTM, Bohnen NI. Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep 2013;13:37786.
  • 26
    Bohnen NI, Frey KA, Studenski S et al. Gait speed in Parkinson's disease correlates with cholinergic degeneration. Neurology 2013;81:16116.
  • 27
    Benarroch EE. Pedunculopontine nucleus: functional organization and clinical implications. Neurology 2013;80:114855.
  • 28
    Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer′s disease. J Comp Neurol 2013;521:412444.